TY - JOUR
T1 - Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation
AU - Wasner, Kobi
AU - Smajic, Semra
AU - Ghelfi, Jenny
AU - Delcambre, Sylvie
AU - Prada-Medina, Cesar A.
AU - Knappe, Evelyn
AU - Arena, Giuseppe
AU - Mulica, Patrycja
AU - Agyeah, Gideon
AU - Rakovic, Aleksandar
AU - Boussaad, Ibrahim
AU - Badanjak, Katja
AU - Ohnmacht, Jochen
AU - Gérardy, Jean Jacques
AU - Takanashi, Masashi
AU - Trinh, Joanne
AU - Mittelbronn, Michel
AU - Hattori, Nobutaka
AU - Klein, Christine
AU - Antony, Paul
AU - Seibler, Philip
AU - Spielmann, Malte
AU - Pereira, Sandro L.
AU - Grünewald, Anne
N1 - Funding Information:
We express our gratitude to the tissue donors and their families for their generous participation. Postmortem tissue for this study was provided by the Newcastle Brain Tissue Resource and Juntendo University. Moreover, Prof. Dr. Doug Turnbull (Wellcome Trust Centre for Mitochondrial Research, Newcastle University) kindly provided fibroblasts for the study from a patient with Alper's disease. We are grateful to Thea Maria Van Wüllen (Luxembourg Centre for Systems Biomedicine) and Carola Dietrich (Max‐Planck‐Institute for Human Molecular Genetics, Berlin) for their assistance in postmortem sample preparation for single‐cell RNA sequencing. We thank Nassima Ouzren and Ursula Heins‐Marroquin for optimizing protocols for experiments used in the study. In addition, the authors thank Dr. Christian Jäger and Xiangyi Dong from the Luxembourg Centre for Systems Biomedicine Metabolomics Platform for the generation of metabolomics data. Finally, this project was supported by the Imaging Facility and the Disease Modelling and Screening Platform, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, and Luxembourg Institute of Health, Luxembourg. Open access funding enabled and organized by Projekt DEAL.
Funding Information:
K.W., J.G., G. Arena, S.L.P., and A.G. were supported by the Luxembourg National Research Fund (FNR) within the ATTRACT program (Model‐IPD, FNR9631103). A.G. and S.L.P were generously supported by a donation from Le Foyer Assurances Luxembourg and obtained funding from the FNR within the framework of PARK‐QC DTU (PRIDE17/12244779/PARK‐QC). S.L.P. was further supported by the FNR INTER Mobility scheme (INTER/MOBILITY/19/13512561). In addition, A.G. and G. Arena are supported by an FNR CORE grant (MiRisk‐PD, C17/BM/11676395). A.G., J.G., and S.D. received funding through an FNR INTER grant (ProtectMove, FNR11250962 and INTER/DFG/19/14429377) and via a grant from The Michael J. Fox Foundation within the framework of the Mitochondrial Biomarkers Spring 2018 program. In addition, P.M. and S.S. were supported by the FNR via the PARK‐QC DTU (PRIDE17/12244779/PARK‐QC) and G. Agyeah obtained funding from the FNR within the framework of the iTRON DTU (PRIDE19/14254520/i2TRON). K.B. received funding from the FNR within the framework of the PRIDE program (CriTiCS, FNR10907093). The work of I.B., J.O., and P.A. was supported by an Excellence Grant of the FNR within the PEARL program (FNR/P13/6682797 awarded to Rejko Krüger). M.M. and J.‐J.G. were supported by an FNR PEARL Excellence Grant (P16/BM/11192868). Moreover, I.B., P.A., and A.G. received funding from the FNR as part of the National Centre of Excellence in Research on Parkinson's disease initiative. J.O. is supported by a Postdoctoral Grant of the Pelican Foundation, Luxembourg. A.G. (GR 3731/5‐1, GR 3731/5‐2), A.R., C.K., E.K., P.S., and J.T. are supported by the German Research Foundation, DFG (Research Unit ProtectMove, FOR 2488). M.S. and C.A.P.‐M. are supported by grants from the DFG (SP1532/3‐1, SP1532/4‐1 and SP1532/5‐1), the Max Planck Foundation and the Deutsches Zentrum für Luft‐und Raumfahrt (DLR 01GM1925). N.H. is supported by the Japan Society for Promotion of Science (Grant‐in‐Aid for Scientific Research [A]; 18H04043, 21H04820), the Japan Agency for Medical Research and Development (Grant‐in‐Aid for Challenging Research [Exploratory]; 19K22603), the Health Labour Sciences Research Grant (JP20dm0307101, JP20dm0207070, JP20ek0109358, JP19ek0109393, JP19gm0710011, JP19km0405206), and the Japan Science and Technology Agency (20FC1049, H29‐FC1‐062, H29‐FC1‐033). The Newcastle Brain Tissue Resource is supported by the UK MRC (MR/L016451/1), the Alzheimer's Society, and Alzheimer's Research Trust through the Brains for Dementia Research Initiative and receives funding from the National Institutes for Health Research Biomedical Research Centre Newcastle. 2
Funding Information:
Kobi Wasner, Semra Smajic, Jenny Ghelfi, Sylvie Delcambre, Giuseppe Arena, Patrycja Mulica, Gideon Agyeah, Ibrahim Boussaad, Katja Badanjak, and Paul Antony report grants from the Luxembourg National Research Fund (FNR) and employment with the University of Luxembourg. Cesar A. Prada‐Medina reports grants from the German Research Foundation (DFG), Max Planck Foundation, and Deutsches Zentrum für Luft‐und Raumfahrt (DLR) and employment with the Max Planck Institute for Molecular Genetics Berlin and University of Oxford. Evelyn Knappe reports employment with the University of Lübeck. Aleksandar Rakovic and Philip Seibler report grants from the DFG and employment with the University of Lübeck. Jochen Ohnmacht reports grants from the FNR and Pelican Foundation and employment with the University of Luxembourg. Jean‐Jacques Gérardy reports grants from the FNR and employment with Laboratoire National de Santé Luxembourg. Masashi Takanashi reports employment with Juntendo University. Joanne Trinh reports grants from the Peter and Traudl Engelhorn Fellowship, Canadian Institutes of Health Research (CIHR) Fellowship, Joachim Herz Stiftung Add‐on Fellowship, and the DFG and employment with the University of Luebeck. Michel Mittelbronn reports employment with the University of Luxembourg, Laboratoire National de Santé Luxembourg, Luxembourg Center of Neuropathology, Luxembourg Institute of Health, and University of Luxembourg. Nobutaka Hattori reports grants from the Japan Society for Promotion of Science, Japan Agency for Medical Research and Development, and Japan Science and Technology Agency; a Health Labour Sciences Research Grant; and employment with Juntendo University. Christine Klein reports consultancies as medical advisor to Centogene and Biogen; honoraria from the Wellcome Trust Review Board; member of the scientific advisory board of the Else Kroener Fresenius Foundation; grants from the Movement Disorder Society, Hermann and Lilly Schilling Foundation, DFG, the German Federal Ministry of Education and Research (BMBF), and European Community; intramural funds from the University of Luebeck; and employment with the University of Luebeck; and royalties from Oxford University Press. Malte Spielmann reports grants from the DFG, Max Planck Foundation, and DLR and employment with the University of Lübeck. Sandro L. Pereira reports grants from the FNR and Le Foyer Assurances Luxembourg and employment with the University of Luxembourg and Luxembourg Institute of Health. Anne Grünewald reports grants from the FNR, DFG, The Michael J. Fox Foundation, and Le Foyer Assurances Luxembourg and employment with the University of Luxembourg.
Publisher Copyright:
© 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
PY - 2022/7
Y1 - 2022/7
N2 - Background: Mutations in the E3 ubiquitin ligase parkin cause autosomal recessive Parkinson's disease (PD). Together with PTEN-induced kinase 1 (PINK1), parkin regulates the clearance of dysfunctional mitochondria. New mitochondria are generated through an interplay of nuclear- and mitochondrial-encoded proteins, and recent studies suggest that parkin influences this process at both levels. In addition, parkin was shown to prevent mitochondrial membrane permeability, impeding mitochondrial DNA (mtDNA) escape and subsequent neuroinflammation. However, parkin's regulatory roles independent of mitophagy are not well described in patient-derived neurons. Objectives: We sought to investigate parkin's role in preventing neuronal mtDNA dyshomeostasis, release, and glial activation at the endogenous level. Methods: We generated induced pluripotent stem cell (iPSC)–derived midbrain neurons from PD patients with parkin (PRKN) mutations and healthy controls. Live-cell imaging, proteomic, mtDNA integrity, and gene expression analyses were employed to investigate mitochondrial biogenesis and genome maintenance. To assess neuroinflammation, we performed single-nuclei RNA sequencing in postmortem tissue and quantified interleukin expression in mtDNA/lipopolysaccharides (LPS)-treated iPSC-derived neuron–microglia co-cultures. Results: Neurons from patients with PRKN mutations revealed deficits in the mitochondrial biogenesis pathway, resulting in mtDNA dyshomeostasis. Moreover, the energy sensor sirtuin 1, which controls mitochondrial biogenesis and clearance, was downregulated in parkin-deficient cells. Linking mtDNA disintegration to neuroinflammation, in postmortem midbrain with PRKN mutations, we confirmed mtDNA dyshomeostasis and detected an upregulation of microglia overexpressing proinflammatory cytokines. Finally, parkin-deficient neuron–microglia co-cultures elicited an enhanced immune response when exposed to mtDNA/LPS. Conclusions: Our findings suggest that parkin coregulates mitophagy, mitochondrial biogenesis, and mtDNA maintenance pathways, thereby protecting midbrain neurons from neuroinflammation and degeneration.
AB - Background: Mutations in the E3 ubiquitin ligase parkin cause autosomal recessive Parkinson's disease (PD). Together with PTEN-induced kinase 1 (PINK1), parkin regulates the clearance of dysfunctional mitochondria. New mitochondria are generated through an interplay of nuclear- and mitochondrial-encoded proteins, and recent studies suggest that parkin influences this process at both levels. In addition, parkin was shown to prevent mitochondrial membrane permeability, impeding mitochondrial DNA (mtDNA) escape and subsequent neuroinflammation. However, parkin's regulatory roles independent of mitophagy are not well described in patient-derived neurons. Objectives: We sought to investigate parkin's role in preventing neuronal mtDNA dyshomeostasis, release, and glial activation at the endogenous level. Methods: We generated induced pluripotent stem cell (iPSC)–derived midbrain neurons from PD patients with parkin (PRKN) mutations and healthy controls. Live-cell imaging, proteomic, mtDNA integrity, and gene expression analyses were employed to investigate mitochondrial biogenesis and genome maintenance. To assess neuroinflammation, we performed single-nuclei RNA sequencing in postmortem tissue and quantified interleukin expression in mtDNA/lipopolysaccharides (LPS)-treated iPSC-derived neuron–microglia co-cultures. Results: Neurons from patients with PRKN mutations revealed deficits in the mitochondrial biogenesis pathway, resulting in mtDNA dyshomeostasis. Moreover, the energy sensor sirtuin 1, which controls mitochondrial biogenesis and clearance, was downregulated in parkin-deficient cells. Linking mtDNA disintegration to neuroinflammation, in postmortem midbrain with PRKN mutations, we confirmed mtDNA dyshomeostasis and detected an upregulation of microglia overexpressing proinflammatory cytokines. Finally, parkin-deficient neuron–microglia co-cultures elicited an enhanced immune response when exposed to mtDNA/LPS. Conclusions: Our findings suggest that parkin coregulates mitophagy, mitochondrial biogenesis, and mtDNA maintenance pathways, thereby protecting midbrain neurons from neuroinflammation and degeneration.
KW - induced pluripotent stem cells
KW - mitochondrial DNA
KW - parkin; neuroinflammation
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=85128726200&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/35460111
U2 - 10.1002/mds.29025
DO - 10.1002/mds.29025
M3 - Article
C2 - 35460111
AN - SCOPUS:85128726200
SN - 0885-3185
VL - 37
SP - 1405
EP - 1415
JO - Movement Disorders
JF - Movement Disorders
IS - 7
ER -